SCHEDULE: T. Rowe Price Discloses 9.9% Stake in Ascendis Pharma

T. Rowe Price Investment Management, Inc. has reported beneficial ownership of 9.9% of Ascendis Pharma A/S - ADR, holding 6,162,042 shares.

Summary

• T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, indicating it beneficially owns 6,162,042 shares of Ascendis Pharma A/S - ADR.
• This holding represents 9.9% of the class of securities.
• The filing specifies sole voting power for 5,884,715 shares and sole dispositive power for 6,162,042 shares.
• The filing date is March 31, 2026, with the certification signed on May 7, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing; it reports a significant ownership stake but does not provide operational or financial performance details of the company itself.

Positives

• T. Rowe Price Investment Management, Inc. has taken a significant stake, holding 9.9% of Ascendis Pharma A/S - ADR, which could signal confidence in the company's future prospects.
• The clear reporting of sole voting and dispositive power suggests a well-defined investment position.

Negatives

• The filing is a Schedule 13G, which is an informational filing for passive investors, and does not indicate any intention to influence or control the company's management or policies.

Risks

• As a passive investor, T. Rowe Price's stake does not inherently mitigate any existing business or market risks faced by Ascendis Pharma A/S.
• The filing does not provide details on the specific investment strategy or rationale, leaving potential risks associated with the investment undisclosed.

Future Outlook

This filing is a Schedule 13G, which is an informational filing regarding ownership. It does not contain forward-looking statements or guidance from Ascendis Pharma A/S.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that significant institutional ownership filings like this Schedule 13G from a major asset manager like T. Rowe Price can be a signal of institutional interest in the biotechnology or pharmaceutical sector, particularly for companies like Ascendis Pharma that may be developing novel therapeutics.

Stakeholder Impact

• Shareholders: The increased institutional ownership may be viewed positively, potentially leading to greater analyst coverage and market interest, but the passive nature of the filing means no direct influence on corporate strategy is implied.
• Management: The filing does not suggest any immediate pressure or change in direction from Ascendis Pharma's management due to this passive investment.

Next Steps

• Monitor future filings from T. Rowe Price Investment Management, Inc. for any changes in their stake in Ascendis Pharma A/S - ADR.
• Observe Ascendis Pharma A/S's operational and financial performance for insights into the company's strategic direction and value.

Key Dates

Keywords

Ascendis Pharma, T. Rowe Price, Schedule 13G, ADR, beneficial ownership, investment management, securities filing, stakeholder